New injection aims to tackle hidden heart risk
NCT ID NCT07640217
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an experimental injection called SYH2068 in 120 adults with high lipoprotein(a), a genetic risk factor for heart disease. Participants receive either the drug or a placebo to see if it safely lowers their Lp(a) levels over several months. The goal is to find a new way to manage this stubborn risk factor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYH2068 injection
- What this could lead to
- If successful, this could lead to a new treatment option to lower high lipoprotein(a) levels, potentially reducing heart disease risk.
- What could go wrong
- This is an early Phase 2 trial with only 120 participants, so results may not confirm effectiveness or safety. The drug may not work better than placebo or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PARTICIPANTS WITH ELEVATED LIPOPROTEIN(A) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.